


**Product Name** : KRA-533  
**Cat. No.** : PC-72963  
**CAS No.** : 10161-87-2  
**Molecular Formula** : C<sub>13</sub>H<sub>16</sub>BrNO<sub>3</sub>  
**Molecular Weight** : 314.179  
**Target** : Ras  
**Solubility** : 10 mM in DMSO



### Biological Activity

KRA-533 (NSC112533, KRA533) is a small molecule **KRAS agonist** that binds the GTP/GDP-binding pocket of KRAS.

KRA-533 activates KRAS in association with growth inhibition of NSCLC cells, directly binds and activates WT and mutant KRAS (G12C, G12D and G13D mutant) in an in vitro cell-free system.

KRA-533 activated exogenous WT and S17A but not K117A KRAS mutant in A549 cells, suggest that the Lys117 hydrogen-bond site is required for KRA-533 to bind or activate KRAS.

KRA-533 induces KRAS activation leading to apoptotic and autophagic cell death in human lung cancer cells.

KRA-533 suppresses mutant KRAS lung cancer in xenograft models.

### References

Ke Xu, et al. *Mol Cancer*. 2019; 18: 85.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com